UBS Group AG - PASITHEA THERAPEUTICS CORP ownership

PASITHEA THERAPEUTICS CORP's ticker is and the CUSIP is 70261F103. A total of 5 filers reported holding PASITHEA THERAPEUTICS CORP in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of PASITHEA THERAPEUTICS CORP
ValueSharesWeighting
Q3 2023$40
-98.8%
83
-98.8%
0.00%
Q2 2023$3,393
-58.4%
6,924
-45.6%
0.00%
Q4 2022$8,148
+16.4%
12,732
+133.5%
0.00%
Q3 2022$7,000
-46.2%
5,452
-57.4%
0.00%
Q2 2022$13,000
+30.0%
12,805
+289.2%
0.00%
Q3 2021$10,0003,2900.00%
Other shareholders
PASITHEA THERAPEUTICS CORP shareholders Q3 2021
NameSharesValueWeighting ↓
K2 PRINCIPAL FUND, L.P. 550,000$715,0000.06%
MARK SHEPTOFF FINANCIAL PLANNING, LLC 48,000$62,0000.03%
TWO SIGMA SECURITIES, LLC 18,899$25,0000.00%
VANGUARD GROUP INC 56,583$74,0000.00%
WELLS FARGO & COMPANY/MN 84$00.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
BlackRock Inc. 9,962$13,0000.00%
Citadel Advisors 72,937$95,0000.00%
JPMORGAN CHASE & CO 1,000$1,0000.00%
View complete list of PASITHEA THERAPEUTICS CORP shareholders